10/16/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/30/2024
7:00 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/03/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/28/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/15/2024
4:06 PM | GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
4:01 PM | Keros Therapeutics (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VII LLC (Reporting)
OrbiMed Genesis GP LLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/13/2024
3:12 PM | Keros Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
|
08/07/2024
3:02 PM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
4:15 PM | Keros Therapeutics (Filer)
| Form 424B5 | |
06/17/2024
4:17 PM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
5:07 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/05/2024
3:10 PM | BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
06/05/2024
3:11 PM | BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/04/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/03/2024
3:15 PM | Farzan Nima (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
3:15 PM | GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
3:15 PM | GRAY MARY ANN (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
3:15 PM | Keros Therapeutics (Issuer)
Knowles Julius (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
3:15 PM | Keros Therapeutics (Issuer)
Nussbaum Ran (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
3:15 PM | Kariv Tomer (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
3:15 PM | Keros Therapeutics (Issuer)
Seth Alpna (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/08/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/08/2024
7:03 AM | Keros Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/03/2024
7:00 AM | Keros Therapeutics (Filer)
| Form S-3ASR | |
03/14/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/06/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/05/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/05/2024
7:02 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/28/2024
3:02 PM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/15/2024
7:37 PM | Cooper Simon Peter (Reporting)
Keros Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/15/2024
7:38 PM | Keros Therapeutics (Issuer)
Rovaldi Christopher (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/15/2024
7:40 PM | Keros Therapeutics (Issuer)
Regnante Keith (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/15/2024
7:41 PM | Keros Therapeutics (Issuer)
Seehra Jasbir (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2024
5:38 PM | ALKEON CAPITAL MANAGEMENT LLC (Filed by)
Keros Therapeutics (Subject)
| Form SC 13G/A | |
02/09/2024
8:16 AM | FMR LLC (Filed by)
Keros Therapeutics (Subject)
| Form SC 13G/A | |
01/26/2024
4:26 PM | BlackRock Inc. (Filed by)
Keros Therapeutics (Subject)
| Form SC 13G/A | |
01/09/2024
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/08/2024
3:43 PM | Keros Therapeutics (Issuer)
Regnante Keith (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/04/2024
3:02 PM | Keros Therapeutics (Filer)
| Form 424B5 | |
01/04/2024
3:04 PM | Keros Therapeutics (Subject)
Regnante Keith (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
This Bull Market Indicator called NVDA at $116 (Ad) Every now and again we find an investment idea so incredible we can’t help but share.
And today is one of those rare days…
Except, today we won't be giving you insight on any one particular stock…
But rather, insight on a revolutionary new stock picking indicator…
In fact, within the last year, this indicator has become famous for a multitude of reasons…
But one of the biggest was because of the buy signal it issued on October 18th, 2022.
In fact, on that very day, it said to buy NVDA at $116.37…
Anyone who did would be sitting on a tremendously large return today…
But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here |
01/04/2024
3:04 PM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/03/2024
7:04 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/13/2023
4:20 PM | Keros Therapeutics (Subject)
ORBIMED ADVISORS LLC (Filed by)
| Form SC 13D/A | |
12/11/2023
5:44 PM | Keros Therapeutics (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2023
5:02 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/07/2023
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2023
7:01 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2023
7:06 AM | Keros Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/06/2023
7:11 AM | Keros Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
